Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Plasma chitinase 3-like 1 is persistently elevated during first month after minimally invasive colorectal cancer resection.

Shantha Kumara HM, Gaita D, Miyagaki H, Yan X, Hearth SA, Njoh L, Cekic V, Whelan RL.

World J Gastrointest Oncol. 2016 Aug 15;8(8):607-14. doi: 10.4251/wjgo.v8.i8.607.

2.

Overexpression of CHI3L1 is associated with chemoresistance and poor outcome of epithelial ovarian carcinoma.

Chiang YC, Lin HW, Chang CF, Chang MC, Fu CF, Chen TC, Hsieh SF, Chen CA, Cheng WF.

Oncotarget. 2015 Nov 24;6(37):39740-55. doi: 10.18632/oncotarget.5469.

3.

Serum markers in early-stage and locally advanced melanoma.

Lugowska I, Kowalska M, Fuksiewicz M, Kotowicz B, Mierzejewska E, Koseła-Paterczyk H, Szamotulska K, Rutkowski P.

Tumour Biol. 2015 Nov;36(11):8277-85. doi: 10.1007/s13277-015-3564-2. Epub 2015 May 23.

4.

Circulating glioma biomarkers.

Kros JM, Mustafa DM, Dekker LJ, Sillevis Smitt PA, Luider TM, Zheng PP.

Neuro Oncol. 2015 Mar;17(3):343-60. doi: 10.1093/neuonc/nou207. Epub 2014 Sep 24. Review.

5.

Serum YKL-40 level is associated with the chemotherapy response and prognosis of patients with small cell lung cancer.

Xu CH, Yu LK, Hao KK.

PLoS One. 2014 May 6;9(5):e96384. doi: 10.1371/journal.pone.0096384. eCollection 2014.

6.

YKL-40-A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?

Schultz NA, Johansen JS.

Cancers (Basel). 2010 Jul 12;2(3):1453-91. doi: 10.3390/cancers2031453.

7.

CHI3L1 plays a role in cancer through enhanced production of pro-inflammatory/pro-tumorigenic and angiogenic factors.

Libreros S, Garcia-Areas R, Iragavarapu-Charyulu V.

Immunol Res. 2013 Dec;57(1-3):99-105. doi: 10.1007/s12026-013-8459-y. Review.

8.

Serum YKL-40 Levels in Patients with Gastric Cancer.

Itik V, Kemik O, Kemik A, Dulger AC, Sümer A, Soyoral YU, Begenik H, Purisa S, Kotan C.

Biomark Cancer. 2011 May 4;3:25-30. doi: 10.4137/BIC.S7154. eCollection 2011.

9.

Early detection biomarkers for ovarian cancer.

Sarojini S, Tamir A, Lim H, Li S, Zhang S, Goy A, Pecora A, Suh KS.

J Oncol. 2012;2012:709049. doi: 10.1155/2012/709049. Epub 2012 Dec 23.

10.

Thrombopoietin: a novel candidate tumor marker for the diagnosis of ovarian cancer.

Mermer T, Terek MC, Zeybek B, Ergenoglu AM, Yeniel AO, Ozsaran A, Zekioglu O.

J Gynecol Oncol. 2012 Apr;23(2):86-90. doi: 10.3802/jgo.2012.23.2.86. Epub 2012 Apr 3.

11.

Protein biomarkers of ovarian cancer: the forest and the trees.

Nolen BM, Lokshin AE.

Future Oncol. 2012 Jan;8(1):55-71. doi: 10.2217/fon.11.135. Review.

12.

Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, DeAngelis LM, Holland EC, Hormigo A.

Neuro Oncol. 2011 Nov;13(11):1244-51. doi: 10.1093/neuonc/nor117. Epub 2011 Aug 10.

13.

Potential role of chitinase 3-like-1 in inflammation-associated carcinogenic changes of epithelial cells.

Eurich K, Segawa M, Toei-Shimizu S, Mizoguchi E.

World J Gastroenterol. 2009 Nov 14;15(42):5249-59. Review.

14.

A list of candidate cancer biomarkers for targeted proteomics.

Polanski M, Anderson NL.

Biomark Insights. 2007 Feb 7;1:1-48.

15.

YKL-40 tissue expression and plasma levels in patients with ovarian cancer.

Høgdall EV, Ringsholt M, Høgdall CK, Christensen IJ, Johansen JS, Kjaer SK, Blaakaer J, Ostenfeld-Møller L, Price PA, Christensen LH.

BMC Cancer. 2009 Jan 9;9:8. doi: 10.1186/1471-2407-9-8.

16.

Systematic evaluation of candidate blood markers for detecting ovarian cancer.

Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, Sahota RA, Wong MQ, Wray A, Bergan LA, Drescher CW, McIntosh MW, Brown PO, Nelson BH, Urban N.

PLoS One. 2008 Jul 9;3(7):e2633. doi: 10.1371/journal.pone.0002633.

17.

Identification of differentially expressed genes in fibroblasts derived from patients with Dupuytren's Contracture.

Satish L, LaFramboise WA, O'Gorman DB, Johnson S, Janto B, Gan BS, Baratz ME, Hu FZ, Post JC, Ehrlich GD, Kathju S.

BMC Med Genomics. 2008 Apr 23;1:10. doi: 10.1186/1755-8794-1-10.

18.

Prognostic implications of immunohistochemically detected YKL-40 expression in breast cancer.

Kim SH, Das K, Noreen S, Coffman F, Hameed M.

World J Surg Oncol. 2007 Feb 7;5:17.

19.

Stabilin-1, a homeostatic scavenger receptor with multiple functions.

Kzhyshkowska J, Gratchev A, Goerdt S.

J Cell Mol Med. 2006 Jul-Sep;10(3):635-49. Review.

20.

Circulating YKL-40 levels during human endotoxaemia.

Johansen JS, Krabbe KS, Møller K, Pedersen BK.

Clin Exp Immunol. 2005 May;140(2):343-8.

Supplemental Content

Support Center